Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:G01N33/48

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.102021118984Ausgießform für Biopsien und Verfahren zum Herstellen eines Gewebeblocks mittels einer solchen Ausgießform
DE 26.01.2023
Int.Class G01N 1/36
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
1Sampling; Preparing specimens for investigation
28Preparing specimens for investigation
36Embedding or analogous mounting of samples
Appl.No 102021118984 Applicant Märsch Thomas Inventor Erfinder gleich Anmelder

Die Erfindung betrifft eine Ausgießform (1) zum Herstellen eines Gewebeblocks (20), mit einem Boden (2) und Seitenwänden, die dazu vorgesehen ist, wenigstens eine Gewebeprobe (3) aufzunehmen und mit einem Ausgießmaterial, insbesondere Wachs (9), befüllt zu werden, um die wenigstens eine Gewebeprobe (3) darin einzubetten. Gemäß der Erfindung ist wenigstens ein Bereich (10) des Bodens (2) so rau ausgebildet ist, dass eine Gewebeprobe (3), die darauf gedrückt wird, am Boden (2) haften bleibt und im flüssigen Ausgießmaterial nicht aufschwimmt oder verrutscht, nachdem sie losgelassen wurde. embedded image

2.WO/2023/001982MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION
WO 26.01.2023
Int.Class G01N 33/50
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Appl.No PCT/EP2022/070541 Applicant UNIVERSITÄT BASEL Inventor FLOHR, Alexander
The present invention relates to ligands specifically presented by MR1 molecules to MR1-specific T cells. These ligands are derivatives or analogues of nucleic acid forming bases, particularly ribonucleoside and deoxyribonucleoside adducts occurring in eukaryotic cells under certain conditions. The invention further relates to pharmaceutical preparations and methods for use of such ligands in treatment and research. The invention further relates to pharmaceutical preparations provided with the aim of modulating presentation of MR1 ligands in clinical situations where such modulated presentation of MR1 ligands is of clinical benefit.
3.WO/2023/003917METHODS OF DISEASE DIAGNOSTICS UTILIZING MICROBIAL EXTRACELLULAR VESICLE (MEV) ANALYTES
WO 26.01.2023
Int.Class C12Q 1/689
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6888for detection or identification of organisms
689for bacteria
Appl.No PCT/US2022/037647 Applicant MICRONOMA, INC. Inventor FRARACCIO, Serena
Methods and systems are presented herein for predicting a disease of a subject through a combination of fungal and non-fungal molecular analyte features of a biological sample.
4.WO/2023/003872METHODS FOR MULTI-DIMENSIONAL LABELING OF NUCLEIC ACIDS OF A CELLULAR SAMPLE IN SITU
WO 26.01.2023
Int.Class C12Q 1/6841
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6813Hybridisation assays
6841In situ hybridisation
Appl.No PCT/US2022/037583 Applicant SCALE BIOSCIENCES INC. Inventor STEEMERS, Frank
Provided herein, among other things, is a method to spatially-label nucleic acid barcodes in or on a cellular sample in situ. In some embodiments, the method may comprise: obtaining a cellular sample comprising analytes or derivatives, fixing the analytes to their native location, providing a population of barcoded nucleic acids, and applying a stimulus to distribute the barcoded nucleic acids over the sample thereby differentially labeling areas and analytes of the sample. This process may include repeating the steps one or more times in various dimensions.
5.WO/2023/003887SYSTEMS AND METHODS FOR MONITORING PLATELET ACTIVATION
WO 26.01.2023
Int.Class G01N 33/52
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
52Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper
Appl.No PCT/US2022/037608 Applicant THE REGENTS OF THE UNIVERSITY OF MICHIGAN Inventor MAJOR, Terry
Provided herein are compositions, systems, and methods for monitoring platelet activation. In particular, provided herein are sensor devices for measuring platelet activation and uses thereof.
6.WO/2023/004082COMPOSITIONS AND METHODS FOR DETECTION OF PROSTATE CANCER
WO 26.01.2023
Int.Class C07K 16/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
Appl.No PCT/US2022/037938 Applicant MERCY BIOANALYTICS, INC. Inventor SEDLAK, Joseph Charles
The present disclosure in one aspect provides technologies for detection of prostate cancer, e.g., early detection of prostate cancer. In another aspect, technologies provided herein are useful for selecting and/or monitoring and/or evaluating efficacy of, a treatment administered to a subject determined to have or susceptible to prostate cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by identifying biomarkers in subjects' bodily fluid samples (e.g., blood samples) that are associated with therapeutic response.
7.WO/2023/002943BIOMARKER FOR PREDICTING PROGNOSIS OF CANCER PATIENT, METHOD FOR PREDICTING PROGNOSIS OF CANCER PATIENT, METHOD FOR PREDICTING EFFECT OF CANCER THERAPEUTIC DRUG ON CANCER PATIENT, AND KIT FOR PREDICTING PROGNOSIS OF CANCER PATIENT
WO 26.01.2023
Int.Class C12N 15/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
Appl.No PCT/JP2022/027853 Applicant TOHOKU UNIVERSITY Inventor TAKAI Toshiyuki
A biomarker for predicting the prognosis of a cancer patient, said biomarker comprising immunosuppressive receptor LILRB4 or immunosuppressive receptor LILRB4 gene; a method for predicting the prognosis of a cancer patient, said method comprising a step for measuring the expression level of immunosuppressive receptor LILRB4 or immunosuppressive receptor LILRB4 gene in a biological sample from the cancer patient; a method for predicting the effect of a substance, which inhibits the binding of fibronectin to immunosuppressive receptor LILRB4, as a cancer therapeutic drug on a cancer patient, said method comprising a step for measuring the expression level of immunosuppressive receptor LILRB4 or immunosuppressive receptor LILRB4 gene in a biological sample from the cancer patient; and a kit for predicting the prognosis of a cancer patient, said kit containing a reagent for measuring the expression level of the aforesaid biomarker.
8.WO/2023/003993LABEL-FREE CLASSIFICATION OF CELLS BY IMAGE ANALYSIS AND MACHINE LEARNING
WO 26.01.2023
Int.Class G06T 7/00
GPHYSICS
06COMPUTING; CALCULATING OR COUNTING
TIMAGE DATA PROCESSING OR GENERATION, IN GENERAL
7Image analysis
Appl.No PCT/US2022/037790 Applicant CORIELL INSTITUTE FOR MEDICAL RESEARCH Inventor HUANG, Jian
Technologies are disclosed for distinguishing among different types of cells. Techniques may include receiving a plurality of first images. The plurality of first images may depict first cells of a first type or a second type. Techniques may include, for each of the plurality of first images, receiving an indicator identifying whether the first image depicts a first cell of the first type or the second type. Techniques may include inputting, into a deep-learning (DL) model, the plurality of first images and the indicator for each of the plurality of first images. Techniques may include inputting, into the DL model, a second image comprising a second cell of the first type or the second type. Techniques may include determining whether the second cell is of the first type or the second type based on the plurality of first images and the indicator for each of the plurality of first images.
9.WO/2023/002493DIGITAL MICROFLUIDICS-LIKE MANIPULATION OF ELECTROKINETICALLY PRECONCENTRATED BIOPARTICLE/BIOMOLECULE PLUGS IN CONTINUOUS-FLOW
WO 26.01.2023
Int.Class G01N 1/40
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
1Sampling; Preparing specimens for investigation
28Preparing specimens for investigation
40Concentrating samples
Appl.No PCT/IL2022/050797 Applicant RAMOT AT TEL-AVIV UNIVERSITY LTD. Inventor YOSSIFON, Gilad
Device for concentration of bioparticles for identification comprises one or more capillary flow paths from at least one inlet for advection along the path of bioparticles in a buffer solution, two or more membranes along the flow path, the membranes being individually selectable for electrical powering, thereby to controllably set up a powered membrane region at a location along said path, said powered membrane region causing localized concentration of the bioparticles, digital-like manipulation of the preconcentrated bioparticles plugs, and detection surface immobilized molecular probes located along said flow path to detect the bioparticles following localized concentration.
10.WO/2023/004038METHODS FOR PREDICTING AND/OR MONITORING CANCER TREATMENT RESPONSE USING CHANGES IN CIRCULATING CANCER ASSOCIATED MACROPHAGE-LIKE CELLS (CAMLS)
WO 26.01.2023
Int.Class G01N 33/483
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
483Physical analysis of biological material
Appl.No PCT/US2022/037874 Applicant CREATV MICROTECH INC. Inventor ADAMS, Daniel L.
Means for predicting treatment response in a subject having cancer are disclosed, where the predictions are based comparing the number and size of circulating cancer associated macrophage-like cells (CAMLs) and circulating tumor cells (CTCs) found in biological samples at baseline and after induction of therapy, such as blood, from the subject.